Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Menarini Korea rolled out new pain medicaiton
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 27, 2014 05:15:42
Menarini Korea rolled out its new narcotic painkiller Abstral Sublingual Tabs, it said on October 21.

Abstral, generically known as fentanyl citrate, is approved for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving opioid therapy for their underlying persistent cancer pain.

Abstral dissolves under the tongue within 1 minute to relieve breakthrough cancer pain fast.

Albert Kim, President of Menarini Korea, said, “Abstral will be a meaningful therapeutic option for caner patients due to convenience and rapid action.”
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com